Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

H. Park; G.I. Shapiro; X. Gao; A. Mahipal; J. Starr; M. Furqan; P. Singh; A. Ahrorov; L. Gandhi; A. Ghosh; D. Hickman; P.D. Gallacher; A. Wennborg; E.C. Attar; M.M. Awad; S. Das; E.E. Dumbrava

doi:10.1016/j.esmoop.2022.100573

Back

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

Journal article

Open access

Peer reviewed

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

H. Park, G.I. Shapiro, X. Gao, A. Mahipal, J. Starr, M. Furqan, P. Singh, A. Ahrorov, L. Gandhi, A. Ghosh, …

ESMO open, Vol.7(5), pp.100573-100573

09/07/2022

DOI: 10.1016/j.esmoop.2022.100573

PMCID: PMC9588880

PMID: 36084396

Files and links (1)

url

https://doi.org/10.1016/j.esmoop.2022.100573View

Published (Version of record) Open Access

Abstract

• Eprenetapopt in combination with pembrolizumab was well tolerated with an acceptable safety profile. • Eprenetapopt plus pembrolizumab demonstrated clinical activity in heavily pre-treated patients with solid tumors. • This is the first clinical trial evaluating the combination of a p53 reactivator with immuno-oncology therapy. • This work informs the development of treatment combining immunotherapy with agents targeting specific pathways such as p53.

clinical trial

eprenetapopt

Original Research

p53

pembrolizumab

solid tumors

Details

Title: Subtitle: Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
Creators: H. Park - Washington University in St. Louis
G.I. Shapiro - Dana Farber Cancer Institute, Department of Medical Oncology, Boston, USA
X. Gao - Massachusetts General Hospital
A. Mahipal - Division of Medical Oncology, Department of Oncology, Mayo Clinic Cancer Center, Rochester, USA
J. Starr - Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic Cancer Center, Jacksonville, USA
M. Furqan - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA
P. Singh - Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic Cancer Center, Phoenix, USA
A. Ahrorov - The University of Texas MD Anderson Cancer Center
L. Gandhi - Dana Farber Cancer Institute, Department of Medical Oncology, Boston, USA
A. Ghosh - Memorial Sloan Kettering Cancer Center
D. Hickman - Aprea Therapeutics, Boston, USA
P.D. Gallacher - Aprea Therapeutics, Boston, USA
A. Wennborg - Aprea Therapeutics, Boston, USA
E.C. Attar - Aprea Therapeutics, Boston, USA
M.M. Awad - Dana Farber Cancer Institute, Department of Medical Oncology, Boston, USA
S. Das - Vanderbilt University Medical Center
E.E. Dumbrava - The University of Texas MD Anderson Cancer Center
Resource Type: Journal article
Publication Details: ESMO open, Vol.7(5), pp.100573-100573
DOI: 10.1016/j.esmoop.2022.100573
PMID: 36084396
PMCID: PMC9588880
NLM abbreviation: ESMO Open
ISSN: 2059-7029
eISSN: 2059-7029
Publisher: Elsevier
Language: English
Date published: 09/07/2022
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359942502771

Metrics

16 Record Views

39 Times Cited - Web of Science